Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 7/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | STK16 | O75716 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.54 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.54 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.54 |
| ▸ | MARK3 | P27448 | 3/20 | 0.53 |
| ▸ | MARK4 | Q96L34 | 3/20 | 0.53 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.53 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.53 |
| ▸ | ULK1 | O75385 | 2/20 | 0.53 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.53 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | SIK1 | P57059 | 1/20 | 0.53 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.53 |
| ▸ | MELK | Q14680 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13313535 | 0.94 | IGF1R (0.48) | TBK1NUAK1NTRK1CSF1RTYK2 | |
| SCHEMBL3568807 | 0.83 | IGF1R (0.45) | TBK1MARK3MARK4STK17AIGF1R | |
| SCHEMBL13313533 | 0.80 | SYK (0.50) | ULK1EGFRAURKA | |
| SCHEMBL13313552 | 0.79 | TBK1 (0.43) | TBK1NUAK1NTRK1TYK2STK16 | |
| SCHEMBL13313551 | 0.79 | IGF1R (0.42) | TBK1MARK3MARK4STK17AIGF1R | |
| SCHEMBL13313555 | 0.77 | AURKB (0.44) | IGF1RBRD4KDRAURKA | |
| SCHEMBL3576521 | 0.76 | TBK1 (0.49) | TBK1IGF1RCDK1KDRCDK2 | |
| SCHEMBL4196715 | 0.75 | INSR (0.41) | TBK1MARK3MARK4STK17AIGF1R | |
| SCHEMBL12235687 | 0.74 | IGF1R (0.57) | TBK1NTRK1IGF1RCDK1CDK2 | |
| SCHEMBL4195275 | 0.74 | INSR (0.40) | TBK1MARK3MARK4STK17ASIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2109605-B1 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-02-20 | — | — | EP | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144706-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| WO-2008077885-A2 | 2- [(PHENYLAMINO) -PYRIMIDIN-4YLAMIN0] -CYCLOPENTANE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF KINASES OF THE CELL CYCLE FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144706-A1 | Compounds | MKI67, CCNA1, CCNT1 | TBK1 3976/4885NUAK1 1692/4885NTRK1 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.